Asato Hashinokuchi

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

ASO Visual Abstract: Efficacy of Adjuvant Chemoimmunotherapy Versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

ASO Visual Abstract: Efficacy of Adjuvant Chemoimmunotherapy Versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

Journal: Annals of surgical oncology

Published: June 03, 2026

ASO Author Reflections: Does Lymph Node Dissection Impair the Efficacy of Adjuvant Immune Checkpoint Inhibitors?

ASO Author Reflections: Does Lymph Node Dissection Impair the Efficacy of Adjuvant Immune Checkpoint Inhibitors?

Journal: Annals of surgical oncology

Published: May 19, 2026

Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma.

Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma.

Journal: Japanese journal of clinical oncology

Published: May 03, 2026

Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

Journal: Annals of surgical oncology

Published: November 12, 2025

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Journal: Signal transduction and targeted therapy

Published: September 27, 2025

Evaluation of Federated Learning Using Standardized EHR Data in Japan.

Evaluation of Federated Learning Using Standardized EHR Data in Japan.

Journal: Studies in health technology and informatics

Published: August 08, 2025

ASO Author Reflections: Examining the Outcomes of Adding Immunotherapy to Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-Small Cell Lung Cancer.

ASO Author Reflections: Examining the Outcomes of Adding Immunotherapy to Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-Small Cell Lung Cancer.

Journal: Annals of surgical oncology

Published: June 30, 2025

The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.

The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.

Journal: Annals of surgical oncology

Published: June 20, 2025

Clinical and biological impact of SNAT7 in lung adenocarcinoma: implications for prognosis and treatment.

Clinical and biological impact of SNAT7 in lung adenocarcinoma: implications for prognosis and treatment.

Journal: International journal of clinical oncology

Published: April 02, 2025

Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer.

Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer.

Journal: Annals of surgical oncology

Published: March 24, 2025

Reply to Dr Hooda Z.

Reply to Dr Hooda Z.

Journal: Interdisciplinary cardiovascular and thoracic surgery

Published: March 14, 2025

ASO Author Reflections: Clinical and Biological Significance of POLD2 in Lung Adenocarcinoma.

ASO Author Reflections: Clinical and Biological Significance of POLD2 in Lung Adenocarcinoma.

Journal: Annals of surgical oncology

Published: February 28, 2025

Showing 1-12 of 44

Last Updated: 09/26/2026